CK Life Sciences International (Holdings), Inc. (LSI) Stock Price & Analysis

LSI Stock Chart & Stats

€0.05-€0.00(-1.82%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 0.05 - EUR 0.05
52-Week Range: EUR 0.05 - EUR 0.11
Previous Close: EUR 0.06
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 535.66M
Enterprise Value: EUR 11.92B
Total Cash (Recent Filing): EUR 535.65M
Total Debt (Recent Filing): EUR 6.83B
Price to Earnings (P/E): ―
Beta: 1.14
Next Earnings: Mar 16, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Segment Diversification

Operating across environmental and health-related segments gives CK Life Sciences more than one avenue for revenue generation. Pest-management products and services can provide recurring demand, while health products add a separate commercialization channel and reduce reliance on a single offering.

In-house Capabilities

In-house R&D and commercialization capabilities support control over product development, marketing, and scaling in selected markets. This platform can help the company refresh its portfolio and capture value from successful products over multiple periods, rather than relying solely on external offerings.

Capital Base

Meaningful equity of about HK$3.8B and a stable asset base indicate the company is not thinly capitalized despite recent losses. That foundation provides some capacity to manage operations and pursue product or market initiatives while addressing weaker profitability.

Bears Say

Margin And Earnings Deterioration

Revenue was broadly flat, declining about 1.5% in 2025, while gross margin collapsed to about 14.5% from 30.6% and the company moved into operating losses. This signals weak earnings quality and makes recovery dependent on restoring economics, not simply maintaining sales.

Negative Cash Generation

Operating cash flow turned slightly negative in 2025 and free cash flow fell to about -HK$278M after positive free cash flow in 2020–2024. A sustained reversal would reduce internally generated funding for R&D, expansion, and obligations, increasing reliance on external financing.

Elevated Leverage

Debt-to-equity rose to about 1.75 in 2025, within a persistently elevated range of roughly 1.3–1.8. High leverage alongside operating and net losses can constrain capital allocation, increase financing pressure, and leave less flexibility if business performance remains weak.

CK Life Sciences International (Holdings), Inc. News

CK Life Sciences Narrows Loss as Reorganised R&D Pipeline Advances in Oncology and Pain

CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) has provided an announcement. CK Life Sciences reported an unaudited loss attributable to shareholders of HK$28.7 million for the first half

2M agoLSI 0775

CK Life Sciences Sets August Board Meeting to Approve Interim Results and Dividend

An announcement from CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) is now available. CK Life Sciences International (Holdings) Inc. has scheduled a board meeting in Hong Kong on

3M agoLSI 0775

CK Life Sciences Shareholders Back All AGM Resolutions, Renew Mandates

An update from CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) is now available. Shareholders of CK Life Sciences International (Holdings) Inc. overwhelmingly approved all resolutions at the annual

5M agoLSI 0775

CK Life Sciences announces CEO change as Lance Yuen steps down and Alan Yu returns to top role

CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) has provided an update. CK Life Sciences International (Holdings) Inc. has announced that Executive Director, Vice President and Chief Executive Officer

5M agoLSI 0775

CK Life Sciences details board composition and governance committee roles

An update from CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) is now available. CK Life Sciences International (Holdings) Inc., a Hong Kong-listed life sciences company incorporated in the

5M agoLSI 0775

CK Life Sciences Sets 2026 AGM, Seeks Share Issue Mandate and Fee Changes

CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) has shared an announcement. CK Life Sciences International (Holdings) Inc. has called its 2026 annual general meeting as a hybrid event

6M agoLSI 0775

CK Life Sciences Unit Showcases Preclinical Cancer Vaccine Advances at AACR 2026

CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) has provided an update. CK Life Sciences’ subsidiary Sequencio Therapeutics will present preclinical data from its cancer vaccine pipeline at the

7M agoLSI 0775

CK Life Sciences Deepens R&D Pivot as 2025 Loss Widens on Investment and One-Offs

An update from CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) is now available. CK Life Sciences reported a loss attributable to shareholders of HK$186.8 million for 2025, driven

7M agoLSI 0775

CK Life Sciences Launches Sequencio to Drive Cancer Vaccine Portfolio

CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) just unveiled an update. CK Life Sciences International (Holdings) Inc. has formed Sequencio Therapeutics Company Limited as a wholly owned subsidiary

7M agoLSI 0775

CK Life Sciences Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

An update from CK Life Sciences International (Holdings), Inc. ( ($HK:0775) ) is now available. CK Life Sciences International (Holdings) Inc. has scheduled a board meeting in Hong Kong on

8M agoLSI 0775

LSI FAQ

What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?

CK Life Sciences International (Holdings), Inc. lowest stock price was €0.05 and its highest was €0.11 in the past 12 months.

What is CK Life Sciences International (Holdings), Inc.’s market cap?

CK Life Sciences International (Holdings), Inc.’s market cap is €535.66M.

When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?

CK Life Sciences International (Holdings), Inc. released its earnings results on Aug 11, 2026. The company reported €0 earnings per share for the quarter.

Is CK Life Sciences International (Holdings), Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does CK Life Sciences International (Holdings), Inc. pay dividends?

CK Life Sciences International (Holdings), Inc. does not currently pay dividends.

What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?

CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?

CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.

What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?

CK Life Sciences International (Holdings), Inc. reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went down -1.613%.

Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?

Currently, no hedge funds are holding shares in DE:LSI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CK Life Sciences International (Holdings), Inc. Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description